GEMAROMA

- Gem Aromatics reported a consolidated loss of INR 7.9 crores for Q1 FY27, attributed to higher depreciation from the newly capitalized Dahej facility and increased operating costs as new product verticals are still in the commercialization phase. - Gross and EBITDA margins were impacted by product mix and higher raw material costs in the clove business due to supply disruptions in Madagascar, which are now resolved. - FY27 is identified as a 'ramp-up year' for the new Dahej facility's product verticals (Safranal, cooling agents, phenol derivatives). - Meaningful revenue contribution from cooling agents and Safranal is anticipated from Q3 FY27, with phenol derivatives expected to contribute from Q4 FY27, leading to a significant ramp-up across all new verticals in FY28. - Krystal products are projected to account for over 50% of total revenue by FY28, with new offerings designed to be more margin accretive. - The company expects a lower working capital cycle for Krystal's synthetic products and is expanding its international presence with a new Brazil subsidiary.

- Audio recording of the Q1 FY27 earnings conference call held on August 14, 2026, at 4:00 p.m. IST is available on the company's website.

- Q1FY27 Consolidated Revenue ₹98.9 Cr vs ₹87.6 Cr (▲12.8% YoY) - EBITDA ₹3.3 Cr vs ₹14.9 Cr (▼77.7% YoY) - PAT ₹-7.9 Cr vs ₹8.0 Cr (▼198.6% YoY) - EBITDA Margin 3.3% vs 17.0% (▼1361 bps) - Profitability was impacted by higher non-cash depreciation of ₹9.1 Cr post capitalization of ~₹265 Cr Dahej capex.

- Q1 FY27 Consolidated Revenue ₹98.9 Cr vs ₹87.6 Cr (▲12.8% YoY) - EBITDA ₹3.3 Cr vs ₹14.9 Cr (▼77.7% YoY) - PAT ₹-7.9 Cr vs ₹8.0 Cr (▼198.6% YoY) - EBITDA Margin 3.3% vs 17.0% (▼1361 bps) - Profitability was impacted by higher raw material and operating costs, product mix, and increased depreciation due to Dahej facility capitalization. - Company expects gradual improvement in margins and profitability as capacity utilization improves and new product verticals scale up. - Approved incorporation of a Wholly Owned Subsidiary in Brazil for international market expansion. - New products from Krystal Ingredients (Cooling Agents, Safranal, Phenol Derivatives) are expected to contribute revenue progressively from Q2/Q3/Q4 FY27.

- Q1 FY27 Consolidated Revenue ₹98.85Cr vs ₹87.63Cr (▲12.80% YoY) - EBITDA ₹3.31Cr vs ₹14.86Cr (▼77.72% YoY) - PAT (Loss) ₹7.87Cr vs (Profit) ₹7.98Cr (Moved from profit to loss) - EBITDA Margin 3.35% vs 16.96% (▼1361bps) - Company changed inventory valuation method from Weighted Average Cost to FIFO, applied prospectively from April 1, 2026. The impact on prior periods is not ascertainable.

- Concall Schedule - Concall Date: Friday, August 14, 2026 - Concall Time: 4:00 p.m. IST - Topic: Unaudited financial results for the Quarter ended June 30, 2026 (Q1 FY27).

- The 29th Annual General Meeting (AGM) for FY 2025-26 will be held on August 19, 2026, at 11:30 a.m. (IST) via Video Conferencing/OAVM. - Notice of AGM and Annual Report for FY 2025-26 have been dispatched to members who have not registered their email addresses.

- Notice of the 29th Annual General Meeting (AGM) to be held on August 19, 2026, at 11:30 A.M. IST via Video Conferencing. - Agenda includes adoption of FY 2025-26 financial statements, re-appointment and appointment of directors, approval of KMP remuneration, and appointment of statutory auditors.